Belavium Tablet (Sevelamer Carbonate)

Adult dose

This medicine should be taken with meals 3 times daily. For patients not taking phosphate binders: The recommended initial dose of this medicine is 0.8g to 1.6g. Take 1 to 2 tablets with each meal as follows, according to the serum phosphorus level. Serum phosphorus 5.5 - 7.5 ㎎/dL: Take 1 tablet with each meal, 3 times daily Serum phosphorus 7.5 ㎎/dL or higher: Take 2 tablets with each meal, 3 times daily When switching patients taking sevelamer hydrochloride tablets to this medicine, use the same dose. Dose adjustment may be needed to achieve the target serum phosphorus level. The maximum daily dose of sevelamer carbonate studied in patients with chronic kidney disease receiving dialysis was 14g. 1 tablet per dose, 3 times daily 1 tablet per dose, 3 times daily 2 tablets per dose, 3 times daily 2 tablets per dose, 3 times daily 3 tablets per dose, 3 times daily 3 tablets per dose, 3 times daily When switching between sevelamer carbonate tablets and powder, use the same dose. Dose adjustment may be needed to achieve the target serum phosphorus level. If necessary, increase or decrease the dose of this medicine by 0.8g with meals 3 times daily at 2-week intervals until the target serum phosphorus level is achieved.

This medication must not be used by patients who are allergic to the main ingredient or excipients. It should not be administered to patients with hypophosphatemia or bowel obstruction as it poses a risk of gastrointestinal perforation. Caution should be exercised when administering this medication to patients with bowel stricture or constipation, as it may cause obstruction or perforation. Gastrointestinal side effects such as vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation may occur during treatment, and in severe cases, treatment may need to be halted. Patients undergoing peritoneal dialysis should be aware of the risk of peritonitis and should notify healthcare professionals immediately if symptoms occur to receive appropriate treatment. This medication does not contain calcium or alkaline substances, so patients should have serum calcium levels monitored regularly and take calcium supplements as needed. Long-term use may lead to decreased levels of fat-soluble vitamins A, D, E, K, and folic acid, so regular blood tests to monitor vitamin status are recommended, and supplements should be taken if necessary. Patients with swallowing difficulties or severe gastrointestinal motility disorders should consider the powder form instead and take care when using it. This medication can affect the absorption of other oral medications, so it should be taken at least 1 hour before or 3 hours after other medications. In particular, it should not be taken concurrently with ciprofloxacin, and close observation is required when taken with warfarin, digoxin, enalapril, metoprolol, or iron. Women who are pregnant or may become pregnant should take this medication cautiously and consider the potential risks to the fetus under a physician's guidance. Nursing women should consult healthcare professionals regarding this medication as it is uncertain whether it is excreted in breast milk. Safety and efficacy in children under 18 years of age have not been established, so its use in children is not recommended. No special precautions are necessary for elderly patients, but treatment should start at a lower dose and be monitored closely. When taking this medication, do not crush or chew the tablets but swallow them whole, and store them in their original container away from moisture. There have been no special reports of overdose, but it is important to adhere to the prescribed dosage. There are no studies on the impact of this medication on driving or the operation of machinery, so caution is advised. If severe constipation, persistent abdominal pain, vomiting, or any unusual symptoms occur, discontinue use immediately and consult a healthcare professional. Cases of hypothyroidism have been rarely reported during the use of this medication, so patients taking related medications should undergo regular thyroid function tests. Patients undergoing peritoneal dialysis should carefully monitor for peritonitis symptoms and strictly adhere to aseptic techniques.

• vomiting
• nausea
• diarrhea
• dyspepsia
• abdominal pain
• distension
• constipation
• peritonitis
• hypersensitivity reaction
• itching

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and safety.

Appearance

Oval film-coated tablet of white or light yellow color

Package unit

180 tablets/bottle, 30 tablets/bottle